These results are in line with our and other previous studies claiming that serum levels of IL-10 and TGF-β were increased in patients with CRC in comparison to healthy controls and that CRC patients with worse prognosis had increased systemic concentration of IL-10 compared to patients with better prognosis [11, 42]. This evidence concerns the gene TGFB1 and colorectal carcinoma.